Characteristics and Outcomes of Patients Consulted by a Multidisciplinary Pulmonary Embolism Response Team: 5-Year Experience.
PERT
catheter-based therapies
pulmonary embolism
pulmonary embolism response team
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
30 Jun 2022
30 Jun 2022
Historique:
received:
30
04
2022
revised:
09
06
2022
accepted:
28
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
10
7
2022
Statut:
epublish
Résumé
(1) Background: Pulmonary embolism (PE) is the third most frequent acute cardiovascular condition worldwide. PE response teams (PERTs) have been created to facilitate treatment implementation in PE patients. Here, we report on the 5-year experience of PERT operating in Warsaw, Poland, with regard to the characteristics and outcomes of the consulted patients. (2) Methods: Patients diagnosed with PE between September 2017 and December 2021 were included in the study. Clinical and treatment data were obtained from medical records. Patient outcomes were assessed in-hospital, at a 1- and 12-month follow-up. (3) Results: There were 235 PERT activations. The risk of early mortality was low in 51 patients (21.8%), intermediate-low in 83 (35.3%), intermediate-high in 80 (34.0%) and high in 21 (8.9%) patients. Anticoagulation alone was the most frequently administered treatment in all patient subgroups (altogether 84.7%). Systemic thrombolysis (47.6%) and interventional therapy (52%) were the prevailing treatment options in high-risk patients. The in-hospital mortality was 6.4%. The adverse events during 1-year follow-up included five deaths, two recurrent VTE and two minor bleeding events. (4) Conclusions: Our initial 5-year experience showed that the activity of the local PERT facilitated patient-tailored decision making and the access to advanced therapies, with subsequent low overall mortality and treatment complication rates, confirming the benefits of PERT implementation.
Identifiants
pubmed: 35807097
pii: jcm11133812
doi: 10.3390/jcm11133812
pmc: PMC9267516
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Am J Med. 2020 Nov;133(11):1313-1321.e6
pubmed: 32416175
Pulm Circ. 2019 Jan 11;:2045894018824563
pubmed: 30632901
Circ Cardiovasc Interv. 2017 Feb;10(2):
pubmed: 28213377
Hosp Pract (1995). 2020 Feb;48(1):23-28
pubmed: 31847615
J Geriatr Cardiol. 2020 Aug;17(8):510-518
pubmed: 32952526
Lancet Oncol. 2019 Oct;20(10):e566-e581
pubmed: 31492632
Eur Heart J. 2020 Jan 21;41(4):543-603
pubmed: 31504429
J Thromb Thrombolysis. 2018 Aug;46(2):186-192
pubmed: 29855780
Am J Med. 2007 Oct;120(10):871-9
pubmed: 17904458
Am J Cardiol. 2019 Nov 1;124(9):1465-1469
pubmed: 31495443
Kardiol Pol. 2020 Apr 24;78(4):300-310
pubmed: 32165606
Kardiol Pol. 2021;79(6):706-707
pubmed: 33885273
Hosp Pract (1995). 2014 Feb;42(1):31-7
pubmed: 24566594
Thromb Haemost. 2016 Apr;115(4):800-8
pubmed: 26607486
Thromb Haemost. 2021 Sep;121(9):1237-1245
pubmed: 33641139
Thromb J. 2021 Mar 31;19(1):21
pubmed: 33789658
Am J Med. 2021 Oct;134(10):1260-1264
pubmed: 33631160
Respir Res. 2020 Jun 22;21(1):159
pubmed: 32571318
Pol Arch Intern Med. 2022 Jan 28;132(1):
pubmed: 34851065
Chest. 2016 Aug;150(2):384-93
pubmed: 27006156
Vasc Med. 2018 Feb;23(1):65-71
pubmed: 28920554
J Thromb Thrombolysis. 2019 Jan;47(1):31-40
pubmed: 30242551
Kardiol Pol. 2021;79(7-8):877-878
pubmed: 33926174
Circ Res. 2016 Apr 29;118(9):1340-7
pubmed: 27126645
Cardiol J. 2019;26(6):623-632
pubmed: 31970735
Res Pract Thromb Haemost. 2019 Jun 09;3(3):315-330
pubmed: 31294318
Postepy Kardiol Interwencyjnej. 2021 Jun;17(2):236-238
pubmed: 34400933
N Engl J Med. 2003 Jul 10;349(2):146-53
pubmed: 12853587